{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T23:57:43Z","timestamp":1776211063517,"version":"3.50.1"},"reference-count":158,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T00:00:00Z","timestamp":1700784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Venetoclax is a strongly effective B-cell lymphoma-2 inhibitor (BCL-2) with an ability to selectively restore the apoptotic potential of cancerous cells. It has been proven that in combination with immunotherapy, targeted therapies, and lower-intensity therapies such as hypomethylating agents (HMAs) or low-dose cytarabine (LDAC), the drug can improve overall outcomes for adult patients with acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and multiple myeloma (MM), amongst other hematological malignancies, but its benefit in pediatric hematology remains unclear. With a number of preclinical and clinical trials emerging, the newest findings suggest that in many cases of younger patients, venetoclax combination treatment can be well-tolerated, with a safety profile similar to that in adults, despite often leading to severe infections. Studies aim to determine the activity of BCL-2 inhibitor in the treatment of both primary and refractory acute leukemias in combination with standard and high-dose chemotherapy. Although more research is required to identify the optimal venetoclax-based regimen for the pediatric population and its long-term effects on patients\u2019 outcomes, it can become a potential therapeutic agent for pediatric oncology.<\/jats:p>","DOI":"10.3390\/ijms242316708","type":"journal-article","created":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T06:51:28Z","timestamp":1700808688000},"page":"16708","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Recent Updates in Venetoclax Combination Therapies in Pediatric Hematological Malignancies"],"prefix":"10.3390","volume":"24","author":[{"given":"Maria","family":"Le\u015bniak","sequence":"first","affiliation":[{"name":"Student Scientific Society of Department of Pediatric Hematology, Oncology and Transplantology, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justyna","family":"Lipniarska","sequence":"additional","affiliation":[{"name":"Student Scientific Society of Department of Pediatric Hematology, Oncology and Transplantology, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrycja","family":"Majka","sequence":"additional","affiliation":[{"name":"Student Scientific Society of Department of Pediatric Hematology, Oncology and Transplantology, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8760-0775","authenticated-orcid":false,"given":"Monika","family":"Lejman","sequence":"additional","affiliation":[{"name":"Independent Laboratory of Genetic Diagnostics, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7207-156X","authenticated-orcid":false,"given":"Joanna","family":"Zawitkowska","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology, Oncology and Transplantology, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Voss, A.K., and Strasser, A. (2020). The Essentials of Developmental Apoptosis. F1000Research, 9.","DOI":"10.12688\/f1000research.21571.1"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1126\/science.7878464","article-title":"Apoptosis in the Pathogenesis and Treatment of Disease","volume":"267","author":"Thompson","year":"1995","journal-title":"Science"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1038\/s41423-020-00630-3","article-title":"Necroptosis, Pyroptosis and Apoptosis: An Intricate Game of Cell Death","volume":"18","author":"Bertheloot","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","article-title":"Molecular Mechanisms of Cell Death: Recommendations of the Nomenclature Committee on Cell Death 2018","volume":"25","author":"Galluzzi","year":"2018","journal-title":"Cell Death Differ."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/onc.2009.39","article-title":"BH3-Only Proteins in Apoptosis and beyond: An Overview","volume":"27","author":"Lomonosova","year":"2008","journal-title":"Oncogene"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"603","DOI":"10.18632\/aging.100934","article-title":"Apoptosis as Anticancer Mechanism: Function and Dysfunction of Its Modulators and Targeted Therapeutic Strategies","volume":"8","author":"Pistritto","year":"2016","journal-title":"Aging"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrm3722","article-title":"Control of Apoptosis by the BCL-2 Protein Family: Implications for Physiology and Therapy","volume":"15","author":"Czabotar","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/s41419-019-1407-6","article-title":"BCL-2 Family Isoforms in Apoptosis and Cancer","volume":"10","author":"Warren","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Shamas-Din, A., Kale, J., Leber, B., and Andrews, D.W. (2013). Mechanisms of Action of Bcl-2 Family Proteins. Cold Spring Harb. Perspect. Biol., 5.","DOI":"10.1101\/cshperspect.a008714"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.molcel.2005.02.003","article-title":"BH3 Domains of BH3-Only Proteins Differentially Regulate Bax-Mediated Mitochondrial Membrane Permeabilization Both Directly and Indirectly","volume":"17","author":"Kuwana","year":"2005","journal-title":"Mol. Cell"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S1097-2765(01)00320-3","article-title":"BCL-2, BCL-X(L) Sequester BH3 Domain-Only Molecules Preventing BAX- and BAK-Mediated Mitochondrial Apoptosis","volume":"8","author":"Cheng","year":"2001","journal-title":"Mol. Cell"},{"key":"ref_12","first-page":"1210","article-title":"Targeting Bcl-2 Family Proteins: What, Where, When?","volume":"85","author":"Senichkin","year":"2020","journal-title":"Biochemistry"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a Potent and Selective BCL-2 Inhibitor, Achieves Antitumor Activity While Sparing Platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"6902","DOI":"10.1021\/jm800669s","article-title":"Discovery of an Orally Bioavailable Small Molecule Inhibitor of Prosurvival B-Cell Lymphoma 2 Proteins","volume":"51","author":"Park","year":"2008","journal-title":"J. Med. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nature03579","article-title":"An Inhibitor of Bcl-2 Family Proteins Induces Regression of Solid Tumours","volume":"435","author":"Oltersdorf","year":"2005","journal-title":"Nature"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1158\/0008-5472.CAN-07-1919","article-title":"Mechanisms of Antileukemic Activity of the Novel Bcl-2 Homology Domain-3 Mimetic GX15-070 (Obatoclax)","volume":"68","author":"Konopleva","year":"2008","journal-title":"Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5430","DOI":"10.1182\/blood-2006-10-047951","article-title":"Preclinical Studies of the Pan-Bcl Inhibitor Obatoclax (GX015-070) in Multiple Myeloma","volume":"109","author":"Trudel","year":"2007","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1182\/blood-2012-04-425033","article-title":"Potent Obatoclax Cytotoxicity and Activation of Triple Death Mode Killing across Infant Acute Lymphoblastic Leukemia","volume":"121","author":"Urtishak","year":"2013","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2147\/CE.S42568","article-title":"An Evidence-Based Review of Obatoclax Mesylate in the Treatment of Hematological Malignancies","volume":"8","author":"Goard","year":"2013","journal-title":"Core Evid."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Han, Z., Liang, J., Li, Y., and He, J. (2019). Drugs and Clinical Approaches Targeting the Antiapoptotic Protein: A Review. BioMed Res. Int., 2019.","DOI":"10.1155\/2019\/1212369"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.beha.2019.05.008","article-title":"Venetoclax-Based Therapies for Acute Myeloid Leukemia","volume":"32","author":"Guerra","year":"2019","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_23","unstructured":"(2023, October 10). VENCLEXTA (Venetoclax Tablets) Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/208573s009lbl.pdf."},{"key":"ref_24","unstructured":"US Food and Drug Administration (2023, October 10). FDA Approves Venetoclax for CLL or SLL, with or without 17 p Deletion, after One Prior Therapy, Available online: https:\/\/www.fda.gov\/drugs\/informationondrugs\/approveddrugs\/ucm610308.htm."},{"key":"ref_25","unstructured":"US Food and Drug Administration (2023, October 10). FDA Approves Venetoclax for CLL and SLL, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-venetoclax-cll-and-sll."},{"key":"ref_26","unstructured":"US Food and Drug Administration (2023, October 10). FDA Approves Venetoclax in Combination for AML in Adults, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-regular-approval-venetoclax-combination-untreated-acute-myeloid-leukemia."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","article-title":"Safety and Preliminary Efficacy of Venetoclax with Decitabine or Azacitidine in Elderly Patients with Previously Untreated Acute Myeloid Leukaemia: A Non-Randomised, Open-Label, Phase 1b Study","volume":"19","author":"DiNardo","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax Combined with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax Combined with Low-Dose Cytarabine for Previously Untreated Patients with Acute Myeloid Leukemia: Results from a Phase Ib\/II Study","volume":"37","author":"Wei","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1158\/2159-8290.CD-18-1453","article-title":"Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia","volume":"9","author":"McMahon","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/blood-2020-140182","article-title":"Outcomes of TP53-Mutant Acute Myeloid Leukemia with Venetoclax and Decitabine","volume":"136","author":"Kim","year":"2020","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1470-2045(17)30012-8","article-title":"Venetoclax plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukaemia: A Phase 1b Study","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2016-01-688796","article-title":"The BCL2 Selective Inhibitor Venetoclax Induces Rapid Onset Apoptosis of CLL Cells in Patients via a TP53-Independent Mechanism","volume":"127","author":"Anderson","year":"2016","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1200\/JCO.2017.76.6840","article-title":"Venetoclax for Patients with Chronic Lymphocytic Leukemia with 17p Deletion: Results from the Full Population of a Phase II Pivotal Trial","volume":"36","author":"Stilgenbauer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/annonc\/mdx031","article-title":"Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in Chronic Lymphocytic Leukemia: Results from a Multicenter Study of 683 Patients","volume":"28","author":"Mato","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1200\/JCO.19.00894","article-title":"Ibrutinib Plus Venetoclax in Relapsed\/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study","volume":"37","author":"Hillmen","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_39","unstructured":"Food and Drug Administration (2023, November 12). Approved Drugs Venetoclax (Venclexta) Tablets, Available online: http:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm495351.htm."},{"key":"ref_40","unstructured":"US Food and Drug Administration (2023, November 12). FDA Grants Regular Approval to Venetoclax in Combination for Untreated Acute Myeloid Leukemia, Available online: https:\/\/www.fda.gov\/drugs\/fda-approves-venetoclax-combination-aml-adults."},{"key":"ref_41","unstructured":"Ascentage Pharma (2023, November 12). Ascentage Pharma Received Clearance from U.S. FDA to Proceed with Global Registrational Phase III Clinical Trial for Lisaftoclax (APG-2575) in Previously Treated Patients with CLL\/SLL. Available online: https:\/\/ascentage.com\/ascentage-pharma-received-clearance-from-u-s-fda-to-proceed-with-global-registrational-phase-iii-clinical-trial-for-lisaftoclax-apg-2575-in-previously-treated-patients-with-cll-sll\/."},{"key":"ref_42","unstructured":"Ascentage Pharma (2023, November 12). Ascentage Pharma Announces Its 9th Orphan Drug Designation from the US FDA in 2020, Setting a Record for Chinese Biopharmaceutical Companies. Available online: https:\/\/ascentage.com\/ascentage-pharma-announces-its-9th-orphan-drug-designation-from-the-us-fda-in-2020-setting-a-record-for-chinese-biopharmaceutical-companies\/."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1182\/blood.2019004043","article-title":"How I Treat Relapsed Acute Lymphoblastic Leukemia in the Pediatric Population","volume":"136","author":"Hunger","year":"2020","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1038\/s41375-022-01619-9","article-title":"Relapsed Acute Myeloid Leukemia in Children and Adolescents: Current Treatment Options and Future Strategies","volume":"36","author":"Caldwell","year":"2022","journal-title":"Leukemia"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Rasche, M., Zimmermann, M., Steidel, E., Alonzo, T., Aplenc, R., Bourquin, J.-P., Boztug, H., Cooper, T., Gamis, A.S., and Gerbing, R.B. (2021). Survival Following Relapse in Children with Acute Myeloid Leukemia: A Report from AML-BFM and COG. Cancers, 13.","DOI":"10.3390\/cancers13102336"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3109\/10428199709039010","article-title":"Bcl-2 Expression in Acute Myeloblastic Leukaemia: Relationship with Autonomous Growth and CD34 Antigen Expression","volume":"24","author":"Bradbury","year":"1997","journal-title":"Leuk Lymphoma"},{"key":"ref_47","first-page":"98","article-title":"Bcl-2 Oncoprotein Expression in Acute Myeloid Leukemia","volume":"80","author":"Bensi","year":"1995","journal-title":"Haematologica"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","article-title":"Selective BCL-2 Inhibition by ABT-199 Causes on-Target Cell Death in Acute Myeloid Leukemia","volume":"4","author":"Pan","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1038\/leu.2014.44","article-title":"BCL-2 Family Proteins as 5-Azacytidine-Sensitizing Targets and Determinants of Response in Myeloid Malignancies","volume":"28","author":"Bogenberger","year":"2014","journal-title":"Leukemia"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1016\/S2352-3026(20)30210-6","article-title":"10-Day Decitabine with Venetoclax for Newly Diagnosed Intensive Chemotherapy Ineligible, and Relapsed or Refractory Acute Myeloid Leukaemia: A Single-Centre, Phase 2 Trial","volume":"7","author":"DiNardo","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S1470-2045(20)30060-7","article-title":"Venetoclax in Combination with Cytarabine with or without Idarubicin in Children with Relapsed or Refractory Acute Myeloid Leukaemia: A Phase 1, Dose-Escalation Study","volume":"21","author":"Karol","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.2217\/fon-2018-0121","article-title":"Accelerating Drug Development in Pediatric Cancer: A Novel Phase I Study Design of Venetoclax in Relapsed\/Refractory Malignancies","volume":"14","author":"Place","year":"2018","journal-title":"Future Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e29678","DOI":"10.1002\/pbc.29678","article-title":"Ex Vivo Drug Sensitivity Profiling-Guided Treatment of a Relapsed Pediatric Mixed-Phenotype Acute Leukemia with Venetoclax and Azacitidine","volume":"69","author":"Gonzales","year":"2022","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e29221","DOI":"10.1002\/pbc.29221","article-title":"Azacitidine and Venetoclax for Post-Transplant Relapse in a Case of CBFA2T3\/GLIS2 Childhood Acute Myeloid Leukaemia","volume":"68","author":"Mishra","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e30308","DOI":"10.1002\/pbc.30308","article-title":"Combined Treatment with Venetoclax, Dasatinib, and FLT3 Inhibitors for NUP98-NSD1+\/FLT3-ITD+ Acute Myeloid Leukemia: A Pediatric Case Report","volume":"70","author":"Wen","year":"2023","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e30021","DOI":"10.1002\/pbc.30021","article-title":"Refractory Pediatric Acute Myeloid Leukemia Expressing NUP98-NSD1 Fusion Gene Responsive to Chemotherapy Combined with Venetoclax and Decitabine","volume":"70","author":"Xu","year":"2023","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1059569","DOI":"10.3389\/fped.2022.1059569","article-title":"Case Report: Venetoclax Therapy in a Boy with Acute Myeloid Leukemia in Shwachman Diamond Syndrome","volume":"10","author":"Naviglio","year":"2022","journal-title":"Front. Pediatr."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e30597","DOI":"10.1002\/pbc.30597","article-title":"Case Report: Positive Response to Venetoclax and Azacitidine in the Treatment of Acute Myeloid Leukemia with Myelodysplasia-Related Changes and Blasts of the Mixed T\/Myeloid Phenotype","volume":"70","author":"Wen","year":"2023","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e2200693","DOI":"10.1200\/PO.22.00693","article-title":"Venetoclax and Azacitidine in the Treatment of NPM1-Mutated Donor Cell\u2013Derived Leukemia in a Patient with Fanconi Anemia: Case Report and Literature Review","volume":"7","author":"Ma","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/s41409-022-01877-2","article-title":"Venetoclax-Based Therapy as a Bridge to Allogeneic Hematopoietic Cell Transplantation in Children with Relapsed\/Refractory AML","volume":"58","author":"Pfeiffer","year":"2023","journal-title":"Bone Marrow Transplant."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.3324\/haematol.2022.282637","article-title":"Clinical Responses in Pediatric Patients with Relapsed\/Refractory Leukemia Treated with Azacitidine and Venetoclax","volume":"108","author":"Niswander","year":"2020","journal-title":"Haematologica"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4366","DOI":"10.1182\/bloodadvances.2023010113","article-title":"Venetoclax-Based Therapies in Pediatric Advanced MDS and Relapsed\/Refractory AML: A Multicenter Retrospective Analysis","volume":"7","author":"Masetti","year":"2023","journal-title":"Blood Adv."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e28398","DOI":"10.1002\/pbc.28398","article-title":"Single-Center Pediatric Experience with Venetoclax and Azacitidine as Treatment for Myelodysplastic Syndrome and Acute Myeloid Leukemia","volume":"67","author":"Winters","year":"2020","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Bobeff, K., Pastorczak, A., Urbanska, Z., Balwierz, W., Juraszewska, E., Wachowiak, J., Derwich, K., Samborska, M., Kalwak, K., and Dachowska-Kalwak, I. (2023). Venetoclax Use in Paediatric Haemato-Oncology Centres in Poland: A 2022 Survey. Children, 10.","DOI":"10.3390\/children10040745"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Trabal, A., Gibson, A., He, J., McCall, D., Roth, M., Nu\u00f1ez, C., Garcia, M., Buzbee, M., Toepfer, L., and Bidikian, A. (2023). Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Experience. Cancers, 15.","DOI":"10.3390\/cancers15071983"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e30335","DOI":"10.1002\/pbc.30335","article-title":"Venetoclax in Combination with Chemotherapy as Treatment for Pediatric Advanced Hematologic Malignancies","volume":"70","author":"Marinoff","year":"2023","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10555-020-09846-1","article-title":"The Genomics of Acute Myeloid Leukemia in Children","volume":"39","author":"Conneely","year":"2020","journal-title":"Cancer Metastasis Rev."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1111\/ajco.13367","article-title":"Genetic Aberrations Involved in Relapse of Pediatric Acute Myeloid Leukemia: A Literature Review","volume":"17","author":"Zafar","year":"2021","journal-title":"Asia-Pac. J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3389\/fped.2017.00004","article-title":"MLL-Rearranged Leukemias-An Update on Science and Clinical Approaches","volume":"5","author":"Winters","year":"2017","journal-title":"Front. Pediatr."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/leu.2017.213","article-title":"The MLL Recombinome of Acute Leukemias in 2017","volume":"32","author":"Meyer","year":"2018","journal-title":"Leukemia"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1002\/cncr.30220","article-title":"Changes in Cytogenetics and Molecular Genetics in Acute Myeloid Leukemia from Childhood to Adult Age Groups","volume":"122","author":"Creutzig","year":"2016","journal-title":"Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1200\/JCO.2009.24.8997","article-title":"Cytogenetics of Childhood Acute Myeloid Leukemia: United Kingdom Medical Research Council Treatment Trials AML 10 and 12","volume":"28","author":"Harrison","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41375-022-01746-3","article-title":"Preclinical Efficacy of Azacitidine and Venetoclax for Infant KMT2A-Rearranged Acute Lymphoblastic Leukemia Reveals a New Therapeutic Strategy","volume":"37","author":"Cheung","year":"2023","journal-title":"Leukemia"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"820191","DOI":"10.3389\/fphar.2021.820191","article-title":"Novel Compounds Synergize with Venetoclax to Target KMT2A-Rearranged Pediatric Acute Myeloid Leukemia","volume":"12","author":"Tregnago","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1080\/10428194.2022.2116934","article-title":"Clinical Experience with Venetoclax and Hypomethylating Agents (HMA) in Patients with Newly Diagnosed and Relapsed or Refractory KMT2A-Rearranged Acute Myeloid Leukemia (AML)","volume":"63","author":"Ball","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41375-019-0485-x","article-title":"Genetic Characterization of ABT-199 Sensitivity in Human AML","volume":"34","author":"Bisaillon","year":"2020","journal-title":"Leukemia"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Griffioen, M.S., de Leeuw, D.C., Janssen, J.J.W.M., and Smit, L. (2022). Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies. Cancers, 14.","DOI":"10.3390\/cancers14143456"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1182\/bloodadvances.2019001267","article-title":"Outcomes of Older Patients with NPM1-Mutated AML: Current Treatments and the Promise of Venetoclax-Based Regimens","volume":"4","author":"Lachowiez","year":"2020","journal-title":"Blood Adv."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/leu.2008.313","article-title":"Favorable Prognostic Impact of NPM1 Gene Mutations in Childhood Acute Myeloid Leukemia, with Emphasis on Cytogenetically Normal AML","volume":"23","author":"Hollink","year":"2009","journal-title":"Leukemia"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1182\/blood-2007-02-076604","article-title":"The Incidence and Clinical Significance of Nucleophosmin Mutations in Childhood AML","volume":"110","author":"Brown","year":"2007","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1182\/blood-2018-99-119806","article-title":"PTPN11 Mutations Confer Unique Metabolic Properties and Increase Resistance to Venetoclax and Azacitidine in Acute Myelogenous Leukemia","volume":"132","author":"Stevens","year":"2018","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nm.4439","article-title":"The Molecular Landscape of Pediatric Acute Myeloid Leukemia Reveals Recurrent Structural Alterations and Age-Specific Mutational Interactions","volume":"24","author":"Bolouri","year":"2018","journal-title":"Nat. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1158\/1078-0432.CCR-16-2353","article-title":"Disease Characteristics and Prognostic Implications of Cell Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children\u2019s Oncology Group","volume":"23","author":"Tarlock","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"E202","DOI":"10.1002\/ajh.25146","article-title":"Genetic Biomarkers of Sensitivity and Resistance to Venetoclax Monotherapy in Patients with Relapsed Acute Myeloid Leukemia","volume":"93","author":"Chyla","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1200\/JCO.22.00602","article-title":"Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed\/Refractory Acute Myeloid Leukemia","volume":"40","author":"Daver","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Smith, S.M., Lee, A., Tong, S., Leung, S., Hongo, H., Rivera, J., Sweet-Cordero, A., Michlitsch, J., and Stieglitz, E. (2022). Detection of a GLIS3 Fusion in an Infant with AML Refractory to Chemotherapy. Cold Spring Harb. Perspect. Biol., 8.","DOI":"10.1101\/mcs.a006220"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1158\/1078-0432.CCR-19-1800","article-title":"Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-Positive AML Defines Novel Therapeutic Options: A COG and TARGET Pediatric AML Study","volume":"26","author":"Smith","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Gress, V., Roussy, M., Boulianne, L., Bilodeau, M., Cardin, S., El-Hachem, N., Lisi, V., Khakipoor, B., Rouette, A., and Farah, A. (2023). CBFA2T3::GLIS2 Pediatric Acute Megakaryoblastic Leukemia Is Sensitive to BCL-XL Inhibition by Navitoclax and DT2216. Blood Adv.","DOI":"10.1182\/bloodadvances.2022008899"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1200\/JCO.2011.37.8018","article-title":"Improved Survival for Children and Adolescents with Acute Lymphoblastic Leukemia between 1990 and 2005: A Report from the Children\u2019s Oncology Group","volume":"30","author":"Hunger","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Richter, A., Fischer, E., Holz, C., Schulze, J., Lange, S., Sekora, A., Knuebel, G., Henze, L., Roolf, C., and Murua Escobar, H. (2021). Combined Application of Pan-AKT Inhibitor MK-2206 and BCL-2 Antagonist Venetoclax in B-Cell Precursor Acute Lymphoblastic Leukemia. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22052771"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/ejh.14015","article-title":"Venetoclax-Based Salvage Therapy for Adult Patients with Relapsed\/Refractory Acute Lymphoblastic Leukemia","volume":"111","author":"Canaani","year":"2023","journal-title":"Eur. J. Haematol."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Holz, C., Lange, S., Sekora, A., Knuebel, G., Krohn, S., Murua Escobar, H., Junghanss, C., and Richter, A. (2023). Combined BCL-2 and PI3K\/AKT Pathway Inhibition in KMT2A-Rearranged Acute B-Lymphoblastic Leukemia Cells. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24021359"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Gibson, A., Trabal, A., McCall, D., Khazal, S., Toepfer, L., Bell, D.H., Roth, M., Mahadeo, K.M., Nunez, C., and Short, N.J. (2021). Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancers, 14.","DOI":"10.3390\/cancers14010150"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.clml.2019.09.608","article-title":"Clinical Experience with Venetoclax Combined with Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia","volume":"20","author":"Jabbour","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","article-title":"Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma","volume":"11","author":"Pullarkat","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1182\/blood-2016-03-707414","article-title":"Venetoclax Responses of Pediatric ALL Xenografts Reveal Sensitivity of MLL-Rearranged Leukemia","volume":"128","author":"Khaw","year":"2016","journal-title":"Blood"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/bjh.16773","article-title":"Investigating the Response of Paediatric Leukaemia-Propagating Cells to BCL-2 Inhibitors","volume":"192","author":"Diamanti","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1182\/blood-2018-04-785980","article-title":"How I Treat Infant Leukemia","volume":"133","author":"Brown","year":"2019","journal-title":"Blood"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.3324\/haematol.2022.281443","article-title":"Venetoclax and Dinaciclib Elicit Synergistic Preclinical Efficacy against Hypodiploid Acute Lymphoblastic Leukemia","volume":"108","author":"Pariury","year":"2023","journal-title":"Haematologica"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Summers, R.J., Jain, J., Vasileiadi, E., Smith, B., Chimenti, M.L., Yeung, T.Y., Kelvin, J., Wang, X., Frye, S.V., and Earp, H.S. (2022). Therapeutic Targeting of MERTK and BCL-2 in T-Cell and Early T-Precursor Acute Lymphoblastic Leukemia. Cancers, 14.","DOI":"10.3390\/cancers14246142"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e28865","DOI":"10.1002\/pbc.28865","article-title":"Venetoclax\/Decitabine for a Pediatric Patient with Chronic Myelomonocytic Leukemia","volume":"68","author":"Molina","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_103","first-page":"100313","article-title":"Hyper-CVAD Combined with Venetoclax for Relapsed Pediatric Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Case Report and Literature Review","volume":"17","author":"Abla","year":"2022","journal-title":"Leuk. Res. Rep."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1111\/bjh.18936","article-title":"Successful Treatment of a Chemotherapy-Resistant t(17;19) Paediatric ALL with a Combination of Inotuzumab, Venetoclax and Navitoclax","volume":"202","author":"Gottardi","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1158\/1078-0432.CCR-15-3057","article-title":"Binding of Released Bim to Mcl-1 Is a Mechanism of Intrinsic Resistance to ABT-199 Which Can Be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells","volume":"22","author":"Niu","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ccell.2019.09.008","article-title":"Venetoclax in Lymphoid Malignancies: New Insights, More to Learn","volume":"36","author":"Thijssen","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1182\/blood.2019004326","article-title":"Changes in Bcl-2 Members after Ibrutinib or Venetoclax Uncover Functional Hierarchy in Determining Resistance to Venetoclax in CLL","volume":"136","author":"Haselager","year":"2020","journal-title":"Blood"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrd.2016.253","article-title":"From Basic Apoptosis Discoveries to Advanced Selective BCL-2 Family Inhibitors","volume":"16","author":"Ashkenazi","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41591-018-0243-z","article-title":"Dynamic Molecular Monitoring Reveals That SWI-SNF Mutations Mediate Resistance to Ibrutinib plus Venetoclax in Mantle Cell Lymphoma","volume":"25","author":"Agarwal","year":"2019","journal-title":"Nat. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"6815","DOI":"10.1158\/1078-0432.CCR-19-0832","article-title":"Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia","volume":"25","author":"Ma","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccell.2019.08.005","article-title":"Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies","volume":"36","author":"Liu","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"27696","DOI":"10.1038\/srep27696","article-title":"Targeting MCL-1\/BCL-XL Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia","volume":"6","author":"Lin","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1080\/10428194.2017.1283032","article-title":"Pathways and Mechanisms of Venetoclax Resistance","volume":"58","author":"Bose","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Tahir, S.K., Smith, M.L., Hessler, P., Rapp, L.R., Idler, K.B., Park, C.H., Leverson, J.D., and Lam, L.T. (2017). Potential Mechanisms of Resistance to Venetoclax and Strategies to Circumvent It. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3383-5"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1182\/blood-2011-04-347849","article-title":"Bcl-xL-Inhibitory BH3 Mimetics Can Induce a Transient Thrombocytopathy That Undermines the Hemostatic Function of Platelets","volume":"118","author":"Schoenwaelder","year":"2011","journal-title":"Blood"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/s41419-020-03092-7","article-title":"Identification of BCL-XL as Highly Active Survival Factor and Promising Therapeutic Target in Colorectal Cancer","volume":"11","author":"Scherr","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1172\/JCI39964","article-title":"Mcl1 Haploinsufficiency Protects Mice from Myc-Induced Acute Myeloid Leukemia","volume":"120","author":"Xiang","year":"2010","journal-title":"J. Clin. Investig."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/leu.2017.243","article-title":"Enhancing Venetoclax Activity in Acute Myeloid Leukemia by Co-Targeting MCL1","volume":"32","author":"Teh","year":"2018","journal-title":"Leukemia"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature19830","article-title":"The MCL1 Inhibitor S63845 Is Tolerable and Effective in Diverse Cancer Models","volume":"538","author":"Kotschy","year":"2016","journal-title":"Nature"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"7301","DOI":"10.2147\/OTT.S146228","article-title":"MCL-1 Inhibition in Cancer Treatment","volume":"11","author":"Xiang","year":"2018","journal-title":"Onco Targets Ther."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"5341","DOI":"10.1038\/s41467-018-07551-w","article-title":"Discovery of Mcl-1-Specific Inhibitor AZD5991 and Preclinical Activity in Multiple Myeloma and Acute Myeloid Leukemia","volume":"9","author":"Tron","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1158\/2159-8290.CD-18-0387","article-title":"AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies","volume":"8","author":"Caenepeel","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_123","unstructured":"Oncology Pipeline (2023, November 12). Amgen Inc. A Robust Pipeline Leveraging State-of-the-Art Science and Molecular Engineering Focused on the Pursuit of Transformative Medicines with Large Effects in Serious Diseases. Human Genetic Validation is Used to Strengthen the Evidence Base of as Many of Our Programs as Possible. Available online: https:\/\/www.amgenpipeline.com\/pipeline\/#oncology."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3324\/haematol.2018.205534","article-title":"Concomitant Targeting of BCL2 with Venetoclax and MAPK Signaling with Cobimetinib in Acute Myeloid Leukemia Models","volume":"105","author":"Han","year":"2020","journal-title":"Haematologica"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.leukres.2015.10.010","article-title":"Clinical Activity of Alvocidib (Flavopiridol) in Acute Myeloid Leukemia","volume":"39","author":"Zeidner","year":"2015","journal-title":"Leuk. Res."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/s43018-020-0103-x","article-title":"Integrated Analysis of Patient Samples Identifies Biomarkers for Venetoclax Efficacy and Combination Strategies in Acute Myeloid Leukemia","volume":"1","author":"Zhang","year":"2020","journal-title":"Nat. Cancer"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"e188","DOI":"10.1111\/bjh.16069","article-title":"Characterization of a Novel Venetoclax Resistance Mutation (BCL2 Phe104Ile) Observed in Follicular Lymphoma","volume":"186","author":"Blombery","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","article-title":"Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia","volume":"9","author":"Blombery","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.3324\/haematol.2019.222588","article-title":"Venetoclax Resistance and Acquired BCL2 Mutations in Chronic Lymphocytic Leukemia","volume":"104","author":"Tausch","year":"2019","journal-title":"Haematologica"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1038\/s41467-019-10363-1","article-title":"Structures of BCL-2 in Complex with Venetoclax Reveal the Molecular Basis of Resistance Mutations","volume":"10","author":"Birkinshaw","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1158\/2159-8290.CD-19-0029","article-title":"Gly101Val BCL2 Mutation: One Step Closer to Understanding Venetoclax Resistance in CLL","volume":"9","author":"Thangavadivel","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1182\/blood.2019004205","article-title":"Multiple BCL2 Mutations Cooccurring with Gly101Val Emerge in Chronic Lymphocytic Leukemia Progression on Venetoclax","volume":"135","author":"Blombery","year":"2020","journal-title":"Blood"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1182\/blood-2014-03-560284","article-title":"Acquired Mutations in BCL2 Family Proteins Conferring Resistance to the BH3 Mimetic ABT-199 in Lymphoma","volume":"123","author":"Fresquet","year":"2014","journal-title":"Blood"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood.2022016090","article-title":"Acquired Mutations in BAX Confer Resistance to BH3-Mimetic Therapy in Acute Myeloid Leukemia","volume":"141","author":"Moujalled","year":"2023","journal-title":"Blood"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","article-title":"The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells","volume":"9","author":"Nechiporuk","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1158\/0008-5472.CAN-17-3024","article-title":"Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells","volume":"78","author":"Rahmani","year":"2018","journal-title":"Cancer Res."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1083\/jcb.139.5.1281","article-title":"Movement of Bax from the Cytosol to Mitochondria during Apoptosis","volume":"139","author":"Wolter","year":"1997","journal-title":"J. Cell Biol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"7092","DOI":"10.1038\/sj.onc.1210517","article-title":"Complete Activation of Bax by a Single Site Mutation","volume":"26","author":"Zhou","year":"2007","journal-title":"Oncogene"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1182\/blood-2015-10-675009","article-title":"BCR Signaling Inhibitors Differ in Their Ability to Overcome Mcl-1-Mediated Resistance of CLL B Cells to ABT-199","volume":"127","author":"Bojarczuk","year":"2016","journal-title":"Blood"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/leu.2011.287","article-title":"MEK Inhibition Enhances ABT-737-Induced Leukemia Cell Apoptosis via Prevention of ERK-Activated MCL-1 Induction and Modulation of MCL-1\/BIM Complex","volume":"26","author":"Konopleva","year":"2012","journal-title":"Leukemia"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1182\/blood-2008-08-173310","article-title":"Concurrent Up-Regulation of BCL-XL and BCL2A1 Induces Approximately 1000-Fold Resistance to ABT-737 in Chronic Lymphocytic Leukemia","volume":"113","author":"Vogler","year":"2009","journal-title":"Blood"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1158\/1078-0432.CCR-11-1440","article-title":"Tipping the Noxa\/Mcl-1 Balance Overcomes ABT-737 Resistance in Chronic Lymphocytic Leukemia","volume":"18","author":"Tromp","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"5178","DOI":"10.1182\/blood-2011-01-331702","article-title":"CD40 Stimulation Sensitizes CLL Cells to Lysosomal Cell Death Induction by Type II Anti-CD20 mAb GA101","volume":"118","author":"Jak","year":"2011","journal-title":"Blood"},{"key":"ref_144","first-page":"e302","article-title":"Resistance to ABT-199 Induced by Microenvironmental Signals in Chronic Lymphocytic Leukemia Can Be Counteracted by CD20 Antibodies or Kinase Inhibitors","volume":"100","author":"Thijssen","year":"2015","journal-title":"Haematologica"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"13283","DOI":"10.1073\/pnas.0702654104","article-title":"The Btk Tyrosine Kinase Is a Major Target of the Bcr-Abl Inhibitor Dasatinib","volume":"104","author":"Hantschel","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"708","DOI":"10.3324\/haematol.2018.214882","article-title":"Phenotype-Based Drug Screening Reveals Association between Venetoclax Response and Differentiation Stage in Acute Myeloid Leukemia","volume":"105","author":"Kontro","year":"2020","journal-title":"Haematologica"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","article-title":"Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia","volume":"10","author":"Pei","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"eaax2863","DOI":"10.1126\/scitranslmed.aax2863","article-title":"Inhibition of Mitochondrial Translation Overcomes Venetoclax Resistance in AML through Activation of the Integrated Stress Response","volume":"11","author":"Sharon","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular Patterns of Response and Treatment Failure after Frontline Venetoclax Combinations in Older Patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/ajh.26314","article-title":"Development of TP53 Mutations over the Course of Therapy for Acute Myeloid Leukemia","volume":"96","author":"Alwash","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11523-020-00711-3","article-title":"Targeting Apoptosis in Acute Myeloid Leukemia: Current Status and Future Directions of BCL-2 Inhibition with Venetoclax and Beyond","volume":"15","author":"Choi","year":"2020","journal-title":"Target. Oncol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1182\/blood.2020010167","article-title":"Intact TP-53 Function Is Essential for Sustaining Durable Responses to BH3-Mimetic Drugs in Leukemias","volume":"137","author":"Thijssen","year":"2021","journal-title":"Blood"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1182\/blood-2021-153286","article-title":"Long Term Follow-up and Combined Phase 2 Results of Eprenetapopt (APR-246) and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)","volume":"138","author":"Sallman","year":"2021","journal-title":"Blood"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/leu.2015.18","article-title":"Mutated Ptpn11 Alters Leukemic Stem Cell Frequency and Reduces the Sensitivity of Acute Myeloid Leukemia Cells to Mcl1 Inhibition","volume":"29","author":"Chen","year":"2015","journal-title":"Leukemia"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1038\/bcj.2012.5","article-title":"Targeting MCL-1 Sensitizes FLT3-ITD-Positive Leukemias to Cytotoxic Therapies","volume":"2","author":"Kasper","year":"2012","journal-title":"Blood Cancer J."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1182\/blood-2008-12-196055","article-title":"FLT3-ITD up-Regulates MCL-1 to Promote Survival of Stem Cells in Acute Myeloid Leukemia via FLT3-ITD-Specific STAT5 Activation","volume":"114","author":"Yoshimoto","year":"2009","journal-title":"Blood"},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Watanabe, D., Nogami, A., Okada, K., Akiyama, H., Umezawa, Y., and Miura, O. (2019). FLT3-ITD Activates RSK1 to Enhance Proliferation and Survival of AML Cells by Activating mTORC1 and eIF4B Cooperatively with PIM or PI3K and by Inhibiting Bad and BIM. Cancers, 11.","DOI":"10.3390\/cancers11121827"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"101244","DOI":"10.1016\/j.tranon.2021.101244","article-title":"FLT3 Inhibition by Olverembatinib (HQP1351) Downregulates MCL-1 and Synergizes with BCL-2 Inhibitor Lisaftoclax (APG-2575) in Preclinical Models of FLT3-ITD Mutant Acute Myeloid Leukemia","volume":"15","author":"Fang","year":"2022","journal-title":"Transl. Oncol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/23\/16708\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:29:20Z","timestamp":1760131760000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/23\/16708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,24]]},"references-count":158,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["ijms242316708"],"URL":"https:\/\/doi.org\/10.3390\/ijms242316708","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,24]]}}}